Welcome to our dedicated page for Trinity Biotech Plc SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trinity Biotech plc (TRIB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 20-F annual reports and Form 6-K current reports. As a foreign private issuer listed on the Nasdaq Stock Market, Trinity Biotech uses these filings to furnish information on its human diagnostics and diabetes management business, financing arrangements and governance matters.
Form 6-K reports for TRIB frequently include press releases as exhibits, covering topics such as regulatory approvals for offshored and outsourced manufacturing of its TrinScreen HIV and Uni-Gold HIV rapid tests, expansion of its high-capacity HbA1c column system for the Premier Hb9210 analyzer, collaboration on epigenetic analysis for the EpiCapture prostate cancer test, and regulatory clearance for the PreClara Ratio preeclampsia testing service. Other 6-K filings reference amendments to credit agreements with Perceptive Credit Holdings entities, warrant issuances, and results of annual general meetings, including resolutions on auditor appointment and share capital authorities.
Users interested in Trinity Biotech’s capital structure and risk profile can review filings that discuss its term-loan facility, amendments and restatements of its credit agreement, and arrangements that allow potential conversion of portions of debt and certain obligations into equity. Filings also document interactions with Nasdaq regarding listing requirements, such as notices of non-compliance with minimum bid price and market value of publicly held shares thresholds, and subsequent confirmation that the company has regained compliance.
Stock Titan enhances access to these documents with tools that surface key elements of each filing, helping readers quickly identify material related to product approvals, financing terms, shareholder votes and other regulatory disclosures. This allows investors, analysts and other stakeholders to examine the official record of Trinity Biotech’s activities as reported to the U.S. Securities and Exchange Commission.
Trinity Biotech PLC Schedule 13G shows Novus Diagnostics Ltd. reports beneficial ownership of 1,119,988 American Depositary Shares, representing 5.99% of the ADS class based on 18,710,000 ADS outstanding as reported. The filing states Novus has sole voting and dispositive power for these 1,119,988 ADS.
Trinity Biotech plc entered a standby equity purchase agreement allowing up to
Trinity Biotech plc files a prospectus supplement registering for resale up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs, for sale by selling shareholders.
The supplement also furnishes Form 6-K disclosures: (1) a Nasdaq notice that the company does not meet the MVPHS $15,000,000 requirement and has until
Trinity Biotech plc registered for resale up to 35,282,966 ADSs (each ADS = 20 ordinary shares). The ADSs include 175,537 Commitment ADSs delivered as a structuring fee and up to 35,107,429 ADSs issuable under a Standby Equity Purchase Agreement providing for up to $25,000,000 of ADS purchases.
The Purchase Agreement dated February 24, 2026 allows the company, at its option, to sell ADSs to YA II PN, LTD. during a commitment period ending the earlier of February 24, 2029 or purchase of the commitment amount. Pricing is 0.97× VWAP for a three-Trading-Day period or 0.95× VWAP for a one-Trading-Day period. The prospectus states the Selling Securityholder will pay resale expenses and the company will not receive proceeds from resales; the company may receive gross proceeds up to $25 million only from ADSs it elects to sell to the Investor under the Purchase Agreement. Shares outstanding were reported as 374,406,640 ordinary shares as of February 22, 2026. The filing also discloses Nasdaq bid-price and market-value deficiency notices, with cure periods extending into August 2026.
Trinity Biotech plc has entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., giving the company the right, but not the obligation, to sell up to $25 million of American Depositary Shares (ADSs), each representing 20 class A ordinary shares.
ADSs sold under the agreement will be priced at 95% of the ADS volume‑weighted average price (VWAP) for a one‑day pricing period or 97% of the lowest VWAP over a three‑day period. The facility runs until the earlier of February 24, 2029 or when the full $25 million is purchased, is subject to an effective resale registration statement, and includes a 4.99% beneficial ownership cap for the investor. Trinity Biotech will pay a $35,000 structuring fee and a commitment fee satisfied by issuing 175,537 ADSs.
Trinity Biotech plc received a Nasdaq notice that it no longer meets the Nasdaq Global Select Market requirement that listed securities maintain a minimum market value of publicly held shares of $15,000,000 based on the last 30 consecutive business days.
The company’s ADSs remain listed and trading on the Nasdaq Global Select Market under the symbol TRIB, with no immediate effect from the notice. Trinity Biotech has 180 calendar days, until August 18, 2026, to regain compliance by having its market value of publicly held shares exceed $15,000,000 for at least 10 consecutive business days, or it may seek transfer to The Nasdaq Capital Market if it meets those listing standards.
If it fails to regain compliance or transfer by that date, Nasdaq may move to delist the ADSs, a decision the company could appeal to a hearings panel, though success is not assured.
Trinity Biotech plc filed a prospectus supplement covering the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The supplement incorporates a recent Form 6-K reporting that Nasdaq notified the company its ADSs no longer meet the minimum bid price requirement of US $1.00 per share after trading below that level for 30 consecutive business days. Trinity Biotech has 180 calendar days, until August 10, 2026, to regain compliance while its ADSs, which last traded at $0.77 on February 13, 2026, remain listed on the Nasdaq Global Select Market.
Trinity Biotech plc received a notice from Nasdaq that its American Depositary Shares are not in compliance with the Nasdaq Global Select Market’s minimum bid price requirement of
The company has 180 calendar days, until
If compliance is not regained within this period, the company may qualify for additional time on The Nasdaq Capital Market if it meets the minimum value of publicly held shares requirement of
Trinity Biotech plc filed a Form 6-K highlighting two operational milestones. The company’s Premier Hb9210™ HbA1c analyser, with its next‑generation Buffer A Plus column system, achieved IFCC Gold Classification for 2026, making it the only HbA1c system worldwide to receive this top‑tier certification.
The filing also notes full regulatory approval to begin upstream manufacturing of the Uni‑Gold™ HIV rapid test under an offshored and outsourced model. Management describes this as the final major regulatory milestone in its transformation plan and expects the new model to support gross margin expansion, better working capital efficiency, and improved long‑term scalability.
Perceptive Advisors and related funds filed Amendment No. 7 to update their ownership in Trinity Biotech plc. The reporting persons disclose beneficial ownership of 1,463,058,248 Class A Ordinary Shares, representing 9.9% of the class based on 374,206,640 Ordinary Shares outstanding and assuming exercise and conversion of their instruments to the extent permitted by a Beneficial Ownership Cap.
The position is held through Perceptive Credit Holdings II, L.P. and Perceptive Credit Holdings III, L.P. via a mix of warrants, a Convertible Note, and milestone and contingent payment obligations, including 65,000,000 Ordinary Shares issuable upon warrant exercise and 1,165,048,540 Ordinary Shares represented by 58,252,427 ADSs issuable upon conversion of the Convertible Note at a floor price of $1.03. Similar conversion mechanics apply to the milestone and contingent obligations. All of these instruments are contractually restricted so that exercises or conversions cannot raise the reporting group’s beneficial ownership above the 9.9% Beneficial Ownership Cap, and the reporting persons expressly disclaim beneficial ownership above that level.